Final results of the pivotal twin phase 3 studies of gantenerumab in early Alzheimer's disease (AD) confirm that the investigational antiamyloid agent lowered amyloid plaque burden but did not slow clinical decline in patients with early AD.
At week 116, the change from baseline in the CDR-SB score was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (difference, -0.31; 95% CI, -0.66 to 0.05; P = .10) and 2.82 and 3.01, respectively, in the GRADUATE II trial (difference, -0.19; 95% CI, -0.55 to 0.17; P = .30).
Results for secondary clinical outcomes also did not support a beneficial clinical effect of the drug.
[
add
]
[
|
|
...
]